Key events, in time order
None yet
None yet
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
A clinical-stage biotech developing FB-102, a treatment for autoimmune skin conditions like vitiligo and alopecia areata.
No revenue; operating losses of USD -0.07B in 2025, funded by investors.
No approved products or proprietary platform; competitors like Incyte and Pfizer dominate autoimmune treatments.
